Mitral regurgitation cardiac MRI: Difference between revisions
Jump to navigation
Jump to search
(/* 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of ...) |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
| [[File:Siren.gif|30px|link=Mitral regurgitation resident survival guide]]|| <br> || <br> | | [[File:Siren.gif|30px|link=Mitral regurgitation resident survival guide]]|| <br> || <br> | ||
| [[Mitral regurgitation resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | | [[Mitral regurgitation resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | ||
|} | |} | ||
{{Mitral regurgitation}} | {{Mitral regurgitation}} | ||
| Line 13: | Line 9: | ||
==Overview== | ==Overview== | ||
Cardiac magnetic resonance (CMR) may be beneficial to evaluate the structure and function of the left atrium and left atrium as well as the severity of the mitral regurgitation when echocardiography findings are insufficient. | |||
==2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume= | issue= | pages= | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852 }} </ref>== | ==2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume= | issue= | pages= | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852 }} </ref>== | ||
===Recommendations for Chronic Primary Mitral Regurgitation=== | ===Recommendations for Chronic Primary Mitral Regurgitation=== | ||
| Line 27: | Line 24: | ||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''Noninvasive imaging (stress nuclear/[[positron emission tomography]], [[CMR]], or [[stress echocardiography]]), [[cardiac CT angiography]], or [[cardiac catheterization]], including [[coronary arteriography]], is useful to establish etiology of chronic secondary [[MR]] (stages B to D) and/or to assess myocardial viability, which in turn may influence management of functional [[MR]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']])<nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.'''Noninvasive imaging (stress nuclear/[[positron emission tomography]], [[CMR]], or [[stress echocardiography]]), [[CT angiography|cardiac CT angiography]], or [[cardiac catheterization]], including [[coronary arteriography]], is useful to establish etiology of chronic secondary [[MR]] (stages B to D) and/or to assess myocardial viability, which in turn may influence management of functional [[MR]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|''Level of Evidence: C'']])<nowiki>"</nowiki> | ||
|} | |} | ||
Revision as of 01:55, 3 September 2014
 |
Resident Survival Guide |
|
Mitral Regurgitation Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mitral regurgitation cardiac MRI On the Web |
|
American Roentgen Ray Society Images of Mitral regurgitation cardiac MRI |
|
Risk calculators and risk factors for Mitral regurgitation cardiac MRI |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cardiac magnetic resonance (CMR) may be beneficial to evaluate the structure and function of the left atrium and left atrium as well as the severity of the mitral regurgitation when echocardiography findings are insufficient.
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary[1]
Recommendations for Chronic Primary Mitral Regurgitation
| Class I |
| "1.Cardiac magnetic resonance (CMR) is indicated in patients with chronic primary MR to assess left ventricle and right ventricle volumes, function, or MR severity and when these issues are not satisfactorily addressed by TTE. (Level of Evidence: B)" |
Recommendations for Chronic Secondary Mitral Regurgitation
| Class I |
| "1.Noninvasive imaging (stress nuclear/positron emission tomography, CMR, or stress echocardiography), cardiac CT angiography, or cardiac catheterization, including coronary arteriography, is useful to establish etiology of chronic secondary MR (stages B to D) and/or to assess myocardial viability, which in turn may influence management of functional MR. (Level of Evidence: C)" |
ACC/AHA Guidelines- ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance[2] (DO NOT EDIT)
| “ |
CMR may be used for assessing individuals with valvular heart disease in which evaluation of valvular stenosis, regurgitation, para- or perivalvular masses, perivalvular complications of infectious processes, or prosthetic valve disease are needed. CMR may be useful in identifying serial changes in LV volumes or mass in patients with valvular dysfunction. |
” |
References
- ↑ Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0000000000000029. PMID 24589852.
- ↑ American College of Cardiology Foundation Task Force on Expert Consensus Documents. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA; et al. (2010). "ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents". Circulation. 121 (22): 2462–508. doi:10.1161/CIR.0b013e3181d44a8f. PMC 3034132. PMID 20479157.